The Sun Pharmaceuticals Halol factory in Gujarat was placed under import alert on Thursday by the US Food and Drug Administration.
The Import Alert implies that until the facility complies with CGMP standards, all future shipments of products made at this facility may be denied admission to the US market, according to a statement from the pharmaceutical company to the stock exchanges. The USFDA’s Current Good Manufacturing Practices regulations are referred to as CGMP. Systems for ensuring proper manufacturing process and facility design, monitoring, and control are provided by CGMPs.
14 of the company’s products are exempt from this import alert according to the USFDA, subject to some restrictions.
The statement claims that, with the 14 excluded goods indicated above, deliveries to the US market from the Halol facility accounted for around 3% of the company’s consolidated revenues for the year ending March 31, 2022.
The firm declared that it would take all necessary measures to address these problems and make sure that the regulator was wholly happy with the company’s corrective action. It also indicated that it would continue to collaborate with the USFDA.
It declared that it remained dedicated to providing CGMP-compliant goods to its clients and patients around the world.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…